{"organizations": [], "uuid": "fb04b5840d148b4ff0d635bb4ae21839ddb89f7d", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-sienna-biopharma-announces-first-p/brief-sienna-biopharma-announces-first-patient-dosed-in-first-in-human-trial-of-topical-sna-125-idUSFWN1Q41A4", "country": "US", "domain_rank": 408, "title": "BRIEF-Sienna Biopharma Announces First Patient Dosed In First-In-Human Trial Of Topical SNA-125", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-14T16:14:00.000+02:00", "replies_count": 0, "uuid": "fb04b5840d148b4ff0d635bb4ae21839ddb89f7d"}, "author": "", "url": "https://www.reuters.com/article/brief-sienna-biopharma-announces-first-p/brief-sienna-biopharma-announces-first-patient-dosed-in-first-in-human-trial-of-topical-sna-125-idUSFWN1Q41A4", "ord_in_thread": 0, "title": "BRIEF-Sienna Biopharma Announces First Patient Dosed In First-In-Human Trial Of Topical SNA-125", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "sienna biopharmaceuticals inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "sienna biopharmaceuticals inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "February 14, 2018 / 2:17 PM / in 9 minutes BRIEF-Sienna Biopharma Announces First Patient Dosed In First-In-Human Trial Of Topical SNA-125 Reuters Staff Feb 14 (Reuters) - Sienna Biopharmaceuticals Inc: * SIENNA BIOPHARMACEUTICALS ANNOUNCES FIRST PATIENT DOSED IN FIRST-IN-HUMAN TRIAL OF TOPICAL SNA-125 * SIENNA BIOPHARMACEUTICALS INC - TOP-LINE RESULTS FROM STUDY EXPECTED IN Q3 OF 2018 * SIENNA BIOPHARMACEUTICALS INC - PLAN TO INITIATE SNA-125 PROOF-OF-CONCEPT TRIAL FOR ATOPIC DERMATITIS AND EXPECT THOSE DATA IN SECOND HALF OF 2018 * SIENNA BIOPHARMACEUTICALS- EXPECT TO REPORT TOP-LINE DATA IN 1H 2019 FROM SNA-120 PHASE 2B CLINICAL TRIAL FOR PRURITUS & ASSOCIATED UNDERLYING PSORIASIS Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-02-14T16:14:00.000+02:00", "crawled": "2018-02-14T16:34:12.043+02:00", "highlightTitle": ""}